Moderna's Sales Drop Surprises Wall Street
Generado por agente de IAMarcus Lee
lunes, 13 de enero de 2025, 9:25 am ET1 min de lectura
FDS--
Moderna, the biotechnology company behind the successful COVID-19 vaccine, has surprised investors by predicting a steeper-than-expected sales drop in 2025. The company's shares tumbled in early trading on Monday, January 13, 2025, after it announced that it expects 2025 revenue to range between $1.5 billion and $2.5 billion, down from its previous guidance of $2.5 billion to $3.5 billion issued in September 2024.
Analysts had expected, on average, $2.92 billion in revenue for 2025, according to FactSet. The company's revised guidance indicates a more significant decline in sales than previously anticipated. This unexpected news sent Moderna's stock price down by 17%, or $7.35, to $34.90 in premarket trading.
Moderna's CFO, Jamey Mock, attributed the revised guidance to several factors, including increased competition in the Covid market, falling vaccination rates, timing around manufacturing contracts with a handful of countries, and uncertainty around what advisors to the Centers for Disease Control and Prevention will recommend for RSV revaccination.
Moderna's primary revenue source has been its COVID-19 vaccine, Spikevax, which brought in more than $3 billion in sales in 2024. However, the company is facing increased competition in the Covid market, with Sanofi co-commercializing Novavax's Covid vaccine worldwide. Additionally, vaccination rates have been falling, with a 7% overall decrease in the U.S. retail market in the fall of 2024 compared to the same time in 2023.
Moderna is also speeding up and expanding a cost-cutting plan, expecting to cut cash costs by $1 billion in 2025, with additional cuts planned for 2026. The company is taking steps to preserve its cash and invest in diversifying its portfolio, with plans to launch multiple new products through 2025, including its RSV vaccine and a combination shot targeting Covid and the flu.
Moderna's announcement comes ahead of its presentation at the annual J.P. Morgan Healthcare Conference in San Francisco, where the company will detail its fourth-quarter results on February 14, 2025. Investors will be closely watching the company's progress and its ability to execute on its plans to return to sales growth in 2025 and break even in 2026.
MRNA--
Moderna, the biotechnology company behind the successful COVID-19 vaccine, has surprised investors by predicting a steeper-than-expected sales drop in 2025. The company's shares tumbled in early trading on Monday, January 13, 2025, after it announced that it expects 2025 revenue to range between $1.5 billion and $2.5 billion, down from its previous guidance of $2.5 billion to $3.5 billion issued in September 2024.
Analysts had expected, on average, $2.92 billion in revenue for 2025, according to FactSet. The company's revised guidance indicates a more significant decline in sales than previously anticipated. This unexpected news sent Moderna's stock price down by 17%, or $7.35, to $34.90 in premarket trading.
Moderna's CFO, Jamey Mock, attributed the revised guidance to several factors, including increased competition in the Covid market, falling vaccination rates, timing around manufacturing contracts with a handful of countries, and uncertainty around what advisors to the Centers for Disease Control and Prevention will recommend for RSV revaccination.
Moderna's primary revenue source has been its COVID-19 vaccine, Spikevax, which brought in more than $3 billion in sales in 2024. However, the company is facing increased competition in the Covid market, with Sanofi co-commercializing Novavax's Covid vaccine worldwide. Additionally, vaccination rates have been falling, with a 7% overall decrease in the U.S. retail market in the fall of 2024 compared to the same time in 2023.
Moderna is also speeding up and expanding a cost-cutting plan, expecting to cut cash costs by $1 billion in 2025, with additional cuts planned for 2026. The company is taking steps to preserve its cash and invest in diversifying its portfolio, with plans to launch multiple new products through 2025, including its RSV vaccine and a combination shot targeting Covid and the flu.
Moderna's announcement comes ahead of its presentation at the annual J.P. Morgan Healthcare Conference in San Francisco, where the company will detail its fourth-quarter results on February 14, 2025. Investors will be closely watching the company's progress and its ability to execute on its plans to return to sales growth in 2025 and break even in 2026.
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
Comentarios
Aún no hay comentarios